Author:
Arrieta Oscar,Rosell Rafael,F. Cardona Andrés
Abstract
Precision oncology, defined as molecular profiling of tumors to identify targetable alterations, is rapidly developing, and has entered the mainstream clinical practice. Genomic testing involves stakeholders workingnin a coordinated fashion to deliver high-quality tissue samples to laboratories, where appropriate next-generation sequencing (NGS) molecular analysis leads to actionable results. Clinicians should be familiar with the types of genomic variants reported by the laboratory and the technology used to determine the effects, including limitations of current testing methodologies and reports. Genomic results are best interpreted with multidisciplinary input to reduce uncertainty in clinical recommendations relating to a documented variant
Publisher
Academia Nacional de Medicina (Colombia)
Reference29 articles.
1. Schwartzberg L, Kim ES, Liu D, Schrag D. Precision Oncology: Who, How, What, When, and When Not? Am Soc Clin Oncol Educ Book. 2017;37:160-169. doi: 10.1200/EDBK_174176.
2. Takeuchi S, Okuda S. Knowledge base toward understanding actionable alterations and realizing precision oncology. Int J Clin Oncol. 2019;24(2):123-130. doi: 10.1007/s10147-018-1378-0.
3. Paolillo C, Londin E, Fortina P. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine. Scand J Clin Lab Invest Suppl. 2016;245:S84-91. doi: 10.1080/00365513.2016.1210331.
4. Bumbea H, Vladareanu AM, Voican I, Cisleanu D, Barsan L, Onisai M. Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment. J Med Life. 2010;3(2):162-6.
5. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291(5507):1304-51. doi: 10.1126/ science.1058040.